Back to search

Article

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models

2024-08-05

Abstract excerpt

Muscle-specific kinase (MuSK) orchestrates establishment and maintenance of neuromuscular synapses, which enable muscle contraction. Autoantibodies targeting MuSK cause myasthenia gravis (MG), a disease characterized by fatigable skeletal muscle weakness which requires chronic immunosuppressive treatment and ventilatory support at some point in ∼30% of patients. MuSK autoantibodies are predominantly IgG4 and are b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
373df5d5-e1dd-5c6c-b0ef-41058fd234e8
DOI
10.1101/2024.08.01.606156
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer modelsDOI 10.1101/2024.08.01.606156
ARGX-119, a therapeutic agonist antibody targeting MuSKSemantic proximity
MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificitySemantic proximity
Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravisSemantic proximity
Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSKSemantic proximity
Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravisSemantic proximity
Change of voltage-gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse modelSemantic proximity
Spotlight on MuSK Positive Myasthenia Gravis: Clinical Characteristics, Treatment and OutcomesSemantic proximity
Pathogenesis of myasthenia gravis: update on disease types, models, and mechanismsSemantic proximity
Gene-specific response to MuSK agonist antibody in the treatment of Congenital Myasthenic SyndromesSemantic proximity
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity
Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravisSemantic proximity
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapySemantic proximity
Select a neighboring publication to make it the new centre.